ASCO: AstraZeneca's Tagrisso, Imfinzi break new ground in lung cancer—with one standing ovation

A 50% improvement on the time patients could live without disease progression would typically be considered remarkable for a new drug. AstraZeneca’s Tagrisso just delivered an 84% improvement.

Tagrisso mounted that massive progression-free survival benefit when compared with placebo in unresectable stage 3 EGFR-mutated non-small cell lung cancer (NSCLC) after definitive chemoradiotherapy in the phase 3 LAURA trial.